secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0001193125-23-192735
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

STK-001 70mg achieves 80% median convulsive seizure reduction at 3 months in Dravet syndrome
--------------------------------------------------------------------------------

- 70mg multiple-dose cohort (n=6): median convulsive seizure reduction 80% at 3 months, 89% at 6 months after last dose.
- 30mg and 45mg OLE data show durable seizure reductions and improvements in cognition/behavior per VABS-III and BRIEF-P.
- Safety: generally well-tolerated in 74 patients; one SUSAR attributed to drug; no treatment-related discontinuations.
- Additional Phase 1/2a end-of-study data and Phase 3 planning update expected in Q1 2024 and H1 2024 respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523192735/0001193125-23-192735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523192735/d530062d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-192735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer